Robotic Minimally Invasive Benign Hysterectomy Post-market Clinical Study With the DEXTER Robotic System
MAGENTA
ROBOTIC MINIMALLY INVASIVE HYSTERECTOMY POST-MARKET CLINICAL STUDY WITH THE DEXTER ROBOTIC SURGERY SYSTEM
1 other identifier
observational
112
1 country
2
Brief Summary
The purpose of this post-market, observational study is to collect real-world data under anticipated conditions of use that demonstrates that the device performs as intended (accurate, precise control of surgical instruments) in patients undergoing robotic-assisted and laparoscopic hysterectomy for benign disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2026
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 31, 2026
CompletedFirst Posted
Study publicly available on registry
August 5, 2026
CompletedStudy Start
First participant enrolled
August 7, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2028
August 5, 2026
July 1, 2026
2.3 years
July 31, 2026
July 31, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Primary safety outcome
Occurrence of Clavien-Dindo grades III-V adverse events
up to 42 days after surgery
Primary efficacy outcome
Successful completion of the DEXTER-assisted procedure, i.e. free of any conversion to an open or fully laparoscopic surgical approach
Intraoperative
Interventions
Robotic-assisted and laparoscopic hysterectomy for benign disease with the DEXTER robotic surgery system.
Eligibility Criteria
Adult patients undergoing a hysterectomy for benign disease
You may qualify if:
- Patient is ≥ 22 years of age at time of enrollment/consent
- Patient is planned to undergo robotic-assisted and laparoscopic hysterectomy for benign disease
- Patient agrees to perform the 6-week follow-up assessment as per standard of care
You may not qualify if:
- Any planned concomitant procedures (not including salpingectomy and/or oophorectomy)
- Diagnosed malignant disease on reproductive organs
- Uterus myomatous with fibroid \> 10cm
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Distalmotion SAlead
Study Sites (2)
Cypress surgery center
Wichita, Kansas, 67226, United States
Memorial Hermann-Texas Medical Center - UT Health Houston
Houston, Texas, 77030-1501, United States
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 31, 2026
First Posted
August 5, 2026
Study Start
August 7, 2026
Primary Completion (Estimated)
December 1, 2028
Study Completion (Estimated)
December 1, 2028
Last Updated
August 5, 2026
Record last verified: 2026-07